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Abstract hNRAGE, a neurotrophin receptor p75 interacting
MAGE homologue, is cloned from a human placenta cDNA
library. hNRAGE can inhibit the colony formation of and arrest
cell proliferation at the G1/S and G2/M stages in hNRAGE
overexpressing cells. Interestingly, hNRAGE also increases
the p53 protein level as well as its phosphorylation (Ser392).
Further studies demonstrated that hNRAGE does not a¡ect the
proliferation of mouse p533/3 embryonic ¢broblasts, suggest-
ing that p53 function is required for hNRAGE induced cell cycle
arrest. Moreover, the cell cycle inhibiting protein p21WAF is
induced by hNRAGE in a p53 dependent manner. The data
provide original evidence that hNRAGE arrests cell growth
through a p53 dependent pathway.
2 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Rat neurotrophin receptor p75 interacting MAGE homo-
logue (NRAGE) encodes a melanoma associated antigen gene
(MAGE) family gene that interacts with the intracellular do-
main of the p75 neurotrophin receptor (p75NTR) [1]. The
normal physiological function of this family of genes remains
mostly unknown though more than 25 members have been
identi¢ed in humans [2]. NRAGE has been shown to be in-
volved in cell cycle arrest and apoptotic response upon nerve
growth factor (NGF) binding to p75NTR in neural cells [1].
Recently, NRAGE has also been found to interact with
XIAP, a member of the inhibitor of apoptosis proteins
(IAPs), and to suppress the anti-apoptotic e¡ect of XIAPs,
thus augmenting cell death even in Bcl-2 overexpressing 32D
cells [3].
Necdin is another MAGE member that is expressed in the
neural system [4]. Ectopic expression of necdin in 3T3 cells
can signi¢cantly arrest cell growth without a¡ecting cell via-
bility [5]. Recent studies reveal that necdin can bind to viral
oncoproteins such as large T antigen, E1A and cellular tran-
scription factor E2F [6]. Necdin can also bind p53 protein and
suppress its transcriptional activity [7].
We have cloned a group of tumor cell proliferation regulat-
ing genes by introducing an expressible cDNA library into
human hepatocellular carcinoma cells (so-called functional
screening). One of these genes turned out to be the human
homologue of rat NRAGE that can inhibit hepatocellular
carcinoma cell proliferation. In this paper, we demonstrate
that the tumor suppressor p53, which is reported to be essen-
tial for p75NTR mediated neuron death [8], played a crucial
role for the function of hNRAGE.
2. Materials and methods
2.1. hNRAGE cloning
A mammalian expression cDNA library was constructed from hu-
man placenta. After ¢rst and second cDNA synthesis, cDNA frag-
ments exceeding 2.0 kb were inserted into the mammalian expression
vector pCMV-Script (Stratagene). A total of 0.5 Wg plasmid DNA was
transfected into HepG2 cells, a hepatocellular carcinoma cell line cul-
tured in 96-well plates. After 10 days G418 selection (800 Wg/ml), the
genes that could signi¢cantly arrest cell growth were selected as can-
didate cell growth suppressing genes. hNRAGE is one of the candi-
dates and contains a full open reading frame.
2.2. Adenovirus generation and plasmid construction
The adenovirus carrying the hNRAGE gene was generated and
produced according to the simpli¢ed system introduced by He et al.
[9], in which hNRAGE with a myc tag was inserted between BglII and
HindIII of pShuttle-H1 and recombined with pAdEasy-1 in BJ5183
bacteria, then the virus was generated in 293A cells. hNRAGE was
also subcloned into pEFneo and pEGFPc3 vectors (Clontech). The
small RNA interference plasmid targeting to hNRAGE was con-
structed by inserting a 19-nt fragment into the pSUPPER-EGFP vec-
tor under the control of an H1 promoter. The sequence of the inserted
fragment is GATGAAAGTGCTGAGATTC. Wild-type and mutant
p53 (T81A), p21CIP1=WAF1 luciferase reporter and L-galactosidase re-
porter plasmid were kindly gifted by Dr. Z.M. Yin.
2.3. Cell culture and transfection
The kidney epithelial cell line HEK293 and human hepatocellular
carcinoma cell line HepG2 cells were cultured in Dulbecco’s modi¢ed
Eagle’s medium, U2 OS, a human osteosarcoma cell line carrying the
wild-type p53 gene, was cultured in RPMI 1640, supplemented with
10% (v/v) fetal bovine serum at 37‡C in humidi¢ed air with 5% CO2.
Transfection was performed by a modi¢ed calcium phosphate precip-
itation method or lipofectamine. Transient transfection e⁄ciency was
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monitored by cotransfection of green £uorescent protein (GFP) vector
(s 80%).
2.4. Colony formation assay
U2 OS, HEK293 and HepG2 cells were transfected with pEFneo/
hNRAGE or pEFneo vector and selected with G418 (200 Wg/ml).
After 14 days selection, cells were stained with 0.5% crystal violet in
20% ethanol and photographed. The size and the number of colonies
were counted under a stereomicroscope.
2.5. Cell cycle assay
HEK293 cells transfected with pEGFP-hNRAGE, U2 OS cells and
mouse p533/3 ¢broblasts infected with adenovirus were collected and
¢xed. After incubated in RNase A (1 Wg/ml) for 30 min at 37‡C, the
cells were stained with propidium iodide (50 Wg/ml). Flow cytometric
analysis was performed with FACScan (Becton Dickinson, Mountain
view, CA, USA) with the CellQuest program.
2.6. p21CIP1=WAF1 luciferase assay
pEFneo/hNRAGE (2 Wg/well) and p21CIP1=WAF promoter (0.2 Wg/
well) were co-transfected into HEK293 cells grown to 50% con£uence
in six-well plates with the calcium phosphate precipitation method.
The vehicle vector pEFneo was used as a blank control. L-Galactosi-
dase reporter plasmid (0.1 Wg/well) was included in all transfections as
an internal control to normalize transfection e⁄ciency. Luciferase
activities were determined 48 h after transfection with a luminometer
(Lumat LB 9507) using a detection kit from Promega.
2.7. Immunoblot and antibodies
To detect phosphorylated and total p53 levels, HEK293 cells in-
fected with adenovirus were lysed directly in sodium dodecyl sulfate
sample bu¡er. About 50 Wg of total protein was loaded in each lane
and equal loading was further con¢rmed by blotting against L-actin.
The procedure of immunoblotting followed the method in Molecular
Cloning. Anti-p53 monoclonal (DO-1), polyclonal (FL-393) and anti-
p-p53 (Ser392) antibodies were purchased from Santa Cruz. Anti-
L-tubulin and anti-p21CIP1=WAF antibody were purchased from Sigma.
2.8. Northern blot analysis of NRAGE
The procedure of Northern blotting followed the method in Mo-
lecular Cloning. Total RNA was isolated with Trizol reagent (Clon-
tech) and size fractionated by electrophoresis through a 1% agarose-
formaldehyde gel. After prehybridization, the blots were hybridized
for 16^24 h at 42‡C in bu¡er containing appropriate 32P-labeled
hNRAGE probes randomly primed with the Megaprime DNA label-
ing system (Amersham). The blots were then exposed to X-ray ¢lm
after thorough washing.
2.9. Statistical analysis
Each treatment was repeated at least three times. The signi¢cance
of the di¡erences between the treatments and the corresponding con-
trols was analyzed by the pooled t-test. A probability value of
P6 0.05 was taken as statistically signi¢cant.
3. Results
3.1. hNRAGE cloning
We have cloned a human cell growth repressing gene by
introducing an expressible cDNA library into human hepato-
cellular carcinoma cells in the early part of 2000 and deposited
this gene in EMBL/GenBank data library under accession
number AF258554. Later, Barker et al. cloned a NRAGE
through yeast two-hybrid screening from rat [1]. By sequence
comparison, we found AF258554 is a true homologue of rat
NRAGE. Like it does in neuronal cells, we found AF258554
also inhibited colony formation in a hepatocellular carcinoma
cell line. The name hNRAGE (AF258554) was used for all the
studies in this paper.
3.2. Overexpression of hNRAGE arrested cell growth
To examine the e¡ect of hNRAGE on cell growth, we
Fig. 1. Cell growth inhibition by NRAGE in HEK293 and U2 OS
cells. A: HEK293 and U2 OS cells were transfected with hNRAGE
gene and vehicle, then selected with G418 (200 Wg/ml). Both the
number and size of colonies were signi¢cantly decreased by
NRAGE. B: Cell cycle analysis by FACS. HEK293 and U2 OS
cells were infected with adenovirus carrying human NRAGE or ad-
enovirus vector. Ninety-six hours later, cells were collected and ¢xed
with cold ethanol and then resuspended in 1 ml solution containing
50 mg/ml RNase A and 50 mg/ml propidium iodide. At least 15 000
cells were collected at each treatment by FACScan and analyzed
with the CellQuest program (Becton Dickinson). hNRAGE arrested
the cell cycle mainly at G1/S and G2/M, whereas no apoptosis was
observed. C: Additional expression of hNRAGE was blotted with
c-myc antibody.
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Fig. 2. hNRAGE arrests the cell cycle through a p53 dependent pathway. Adenovirus of NRAGE was used to infect mouse primary ¢broblasts
derived from p53+/+, +/3, and 3/3 mice. The cell cycle suppressing function of hNRAGE was totally inhibited in p533/3 ¢broblasts. The in-
fection e⁄ciency was monitored with GFP expression.
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tested the colony formation ability of U2 OS, HepG2 and
HEK293 cells after transfection with hNRAGE gene. Trans-
fection of hNRAGE resulted in a decrease of the colony num-
ber or size in the three cell lines (Fig. 1A, only the data of U2
OS and HEK293 are shown). To further determine whether
NRAGE induces apoptosis or arrest of cell cycle, FACS anal-
ysis was applied to HEK293 cells transfected with GFP-
hNRAGE gene and U2 OS cells infected with hNRAGE ad-
enovirus. Unexpectedly, no apoptotic cells were found in
hNRAGE overexpressing cells. The number of S phase cells,
however, was decreased signi¢cantly in both cell lines. Ninety-
six hours after infection, the percentage of S phase U2 OS
cells was decreased from 51.56% to 16.27%, whereas the per-
centage at G1 and G2/M phase was increased from 34.08% to
53.45% and 14.36% to 30.28%, respectively (Fig. 1B). Similar
results were observed in HEK293 cell (S phase cells from
42.00% to 19.00%, G1 phase cell from 53.11% to 78.35%).
These data clearly demonstrate that overexpression of
hNRAGE caused cell cycle arrest at G2/M or G1 phase.
Fig. 1C shows that hNRAGE adenovirus infection could
highly increase the protein level of hNRAGE in HEK293
cells.
3.3. p53 was required for cell growth arrest induced by NRAGE
p53 is an important tumor suppressor gene regulating both
cell apoptosis and proliferation. Is p53 involved in hNRAGE
mediated cell cycle arrest? To answer this question, we in-
fected mouse embryonic ¢broblasts (MEF) derived from p53
null, heterozygous and wild-type mice. Two days after infec-
tion, FACS analysis showed that the percentage of S phase
cells was decreased from 53.77% to 26.12%, and G1 phase was
increased from 26.25% to 51.69% in p53+/+ MEF. p53+/3
cells displayed similar number changes (40.54% to 20.38% for
S phase and 40.52% to 66.81% for G1 phase). However,
p533/3MEF showed no signi¢cant change in all G1, S phase
and G2/M phase cell numbers upon hNRAGE overexpression
(Fig. 2), suggesting p53 was required for hNRAGE induced
cell cycle arrest.
3.4. NRAGE a¡ects the phosphorylation and accumulation of
p53
Because Northern blotting showed that the mRNA level of
the p53 gene was not changed by hNRAGE overexpression
(Fig. 3A), hNRAGE might a¡ect p53 activity in a post-tran-
Fig. 3. hNRAGE induces post-translational modi¢cation of p53.
A: Although the mRNA level of NRAGE was very high after over-
expression in HEK293 cells, the mRNA level of p53 remained un-
changed. B: Western blotting showed that both the total protein
level and phosphorylation level of p53 were increased after overex-
pression of hNRAGE in HEK293 cells.
Fig. 4. hNRAGE could induce expression of p21CIP1=WAF through a
p53 dependent pathway. A: NRAGE could stimulate the luciferase
activity that is under the control of the p21CIP1=WAF promoter, but
the p53 mutant (T81A) could abolish the induction of p21 by
NRAGE. B: siRNAi of hNRAGE could eliminate the expression of
hNRAGE in HEK293 cells. siRNA plasmid was co-transfected with
pEGFP-hNRAGE. The expression of GFP-hNRAGE was tested by
GFP antibody. C: The induction of p21 by NRAGE was further
con¢rmed by Western blotting. About 50 Wg of total protein was
loaded in each line.
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scriptional manner through changing its phosphorylation and
accumulation. Western blotting of p53 showed that both the
phosphorylation (Ser392) and the accumulation level of p53
protein were increased signi¢cantly after overexpression of
hNRAGE (Fig. 3B). It is possible that the increase of p53
phosphorylation might account for the elevation of the p53
protein level. These data indicate that hNRAGE could some-
how modify p53 and increase its stability.
3.5. NRAGE could induce p21CIP1=WAF expression in a p53
dependent manner
Because the cell cycle inhibitor protein p21CIP1=WAF is a
downstream target gene of p53, we examined the expression
of p21CIP1=WAF in hNRAGE overexpressing cells. Results re-
vealed that hNRAGE induced an about ¢ve-fold increase in
p21CIP1=WAF-Luc reporter gene activity (Fig. 4A). The results
were further con¢rmed by a loss of function experiment, in
which siRNA of hNRAGE could abolish the stimulation of
hNRAGE overexpression. Fig. 4B shows that siRNA of
hNRAGE could eliminate the expression of GFP-hNRAGE.
The data of the luciferase assay that hNRAGE could induce
p21CIP1=WAF transcriptional activity were further con¢rmed by
Western blotting experiments that the protein level of
p21CIP1=WAF was indeed increased in hNRAGE expressing
cells (Fig. 4C). These results suggest that hNRAGE could
inhibit cell proliferation through increasing the expression of
the cell cycle inhibitor protein p21CIP1=WAF. Moreover, the
upregulation of p21CIP1=WAF by hNRAGE depends on the
p53 activity because this e¡ect was completely abolished
by co-transfection of dominant negative p53 (T81A) (Fig.
4A).
4. Discussion
Over 25 MAGE genes have now been cloned in humans
since the identi¢cation of the ¢rst MAGE gene in 1991. How-
ever, the physiological role of most MAGE proteins remains a
mystery. Recent studies are now beginning to provide insights
into MAGE gene functions. For instance, necdin was found
to regulate the cell cycle and be involved in the pathogenesis
of Prader^Willi syndrome [10]. First identi¢ed as a binding
partner for p75NTR, NRAGE also blocks PC12 cell cycle
progression and enhances apoptosis in the presence of NGF
though little is known about the mechanisms [1].
Our studies found that hNRAGE suppresses cell colony
formation in HEK293, U2 OS and HepG2 cells. The cell cycle
arrest occurs at the G2/M and G1 stage. By using p533/3
MEF, our results clearly proved that p53 activity is required
for the suppression of cell proliferation by hNRAGE. It is
worth mentioning that all the other cell lines we used carry
wild-type p53 [11,12]. In addition, we also demonstrated that
the upregulation of p21WAF expression by hNRAGE also de-
pends on the wild-type p53 activity because dominant nega-
tive mutant p53 completely abolishes hNRAGE’s function.
Moreover, we observed that hNRAGE enhances the phos-
phorylation and accumulation of p53 protein without chang-
ing the mRNA level of p53. Therefore we propose that
hNRAGE upregulates p53 activity through post-transcrip-
tional modi¢cation of p53. This characteristic of hNRAGE
resembles that of the Wilms’ tumor suppressor WT-1 that
binds to p53 directly and enhances p53 dependent transacti-
vation [13]. It will be extremely interesting to further examine
whether and how hNRAGE indirectly or indirectly regulates
the components in the p53 regulation pathway.
Previous studies have indicated that p75NTR can activate
the p53 pathway. When p53 is diminished in p533/3 mice or
ablated using the adenovirus E1B55K protein, p75NTR asso-
ciated sympathetic neuron death is inhibited [8]. But there is
also a report that suggests that p75NTR might also mediate
apoptosis in a p53 independent pathway [14]. So the precise
signaling event linking p75NTR to apoptosis activation is still
unknown. But hNRAGE, based on our data and previous
reports [1,3], can still be thought to be a very important me-
diator of apoptosis and cell proliferation. We speculated that
hNRAGE should act as a protein recruiter or mediator of this
processes. When signal molecule binding to its receptor,
hNRAGE can be activated, for instance bind the intracellular
domain of p75NTR in NGF issue, and then recruit and acti-
vate other proteins such as p53. Actually we really found that
hNRAGE can a¡ect the stability of some intracellular mole-
cules like p53 (Fig. 3) and L-catenin (data not shown). Re-
cently, Salehi et al. have reported that hNRAGE could induce
caspase activation and cell death through the c-Jun N-termi-
nal kinase (JNK)/c-Jun pathway [15]. In response to stress,
JNK is phosphorylated on both Thr-183 and Thr-185 residues
by MKK4/7 [16,17], which then leads to the phosphorylation
of JNK substrates, which include p53 [18,19]. It is unknown
whether hNRAGE induced p53 activation is linked to the
JNK pathway.
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